"Hospital Infanta Cristina de Badajoz (CICAB - Centro de Investigación Clínica del Área de Salud de Badajoz)"
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mingorance, Juan Ignacio Delgado
postMONARCH, NCT05169567: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Checkmark postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy.
Recruiting
3
350
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
08/23
02/26
PRESERVE 2, NCT04799249 / 2020-004930-39: Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

Checkmark Immune profiling to investigate improved survival in patients with metastatic triple-negative breast cancer receiving trilaciclib prior to chemotherapy
Recruiting
3
250
Europe, US, RoW
Trilaciclib, G1T28, COSELA, Placebo, 0.9% normal saline, 5 % Dextrose in water (D5W), Gemcitabine, Carboplatin
G1 Therapeutics, Inc.
TNBC - Triple-Negative Breast Cancer, Breast Cancer
06/24
10/24
PATRICIA, NCT02448420 / 2014-005006-38: Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Checkmark SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast canc…
Checkmark Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study
Checkmark [VIRTUAL] SOLTI-1303 PATRICIA II randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) wit…
Checkmark [VIRTUAL] Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA I…
Checkmark [VIRTUAL] Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA I…
More
Recruiting
2
102
Europe
Palbociclib, Ibrance, Trastuzumab, Herceptin, Endocrine therapy, ET, Chemotherapy, CT, Antibody-Drug Conjugates, Trastuzumab emtansine (TDM-1)
SOLTI Breast Cancer Research Group
Metastatic Breast Cancer
08/23
08/23

Download Options